Objective To explore the clinical effect of Shugan Tablet adjuvant treatment on obese type 2 diabetic gas-tro-paresis patients .Methods From 2012 January to 2013 December , in our hospital , 120 obesity type 2 diabetic gastro-pare sis patients were enrolled , they were randomly divided into 2 groups, the observation group of 65 cases, and 55 cases in the control group, the 2 groups were given conventional therapy , the observation group adds the Shugan Tablets 4 tablets, 2 times every day;the control group did not take any medicine .The 2 groups were treated for 30 days.At the end of the treatment , clinical symptoms score, plasma leptin, glucagon like peptide-1 (GLP-1), gastric emptying rate, level of electrogastrogram were compared between the two groups .Results The clinical symptoms score before and after treatment in the observation group had statistical significant differences , the differences of these index between observation and control group after treatment also significant ( P <0.05).Total effective rate of observation group is higher than that of the control group (90.77% vs. 29.09%, P <0.05).The serum leptin level of observation group after treatment were decreased obviously than before treat -ment and control group after treatment ( P <0.05), no change were found in GLP-1 level before and after treatment ( P <0.05);compared with before treatment , GLP-1 and leptin level had no statistical significance in the control group after treat-ment ( P >0.05).The stomach emptying rate group, average amplitude of electrogastrogram display in the observation group after treatment increased than before treatment and control group after treatment , the differences were statistically significant (P <0.05).Conclusion Shugan tablets could reduce the leptin levels in diabetic patients , thus affecting the gastric emp-tying, clinical curative effect is good , and provide clinical basis for the treatment of obesity and type 2 diabetes mellitus gastro-paresis patients .%目的：探索舒肝片辅治肥胖型2型糖尿病胃轻瘫患者的临床效果。方法选取2012年1月-2013年12月收治的肥胖型2型糖尿病胃轻瘫患者120例，随机分为2组，观察组65例，对照组55例，2组均给予常规降糖治疗，观察组加服舒肝片4片，每天2次；对照组不加服任何药物。2组疗程均为30 d。疗程结束时观察2组临床症状评分、血浆瘦素、胰高血糖素样肽-1（ GLP-1）水平、胃排空率、胃电图变化。结果观察组总有效率高于对照组（90．77％vs．29．09％， P ＜0．05）。观察组治疗后各项临床症状积分及症状总积分与治疗前、对照组治疗后比较差异有统计学意义（ P均＜0．05）。观察组治疗后瘦素水平较治疗前、对照组治疗后降低（ P ＜0．05），GLP-1水平较治疗前无变化（ P ＜0．05）；对照组治疗后瘦素、GLP-1水平与治疗前比较差异无统计学意义（ P ＞0．05）。观察组胃腔排空率、胃电图显示的平均幅值较治疗前及对照组治疗后升高，差异均有统计学意义（ P ＜0．05）。结论舒肝片可降低糖尿病患者体内瘦素水平，从而影响胃排空，临床疗效好，为治疗肥胖型2型糖尿病合并胃轻瘫患者提供临床依据。
展开▼
